Novo Nordisk A/S

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

NVO vs. LLY Stock Comparison

Home

Compare stocks

Compare NVO and LLY: 4.65% vs 0.52% dividend yield, 9.6 vs 40.5 P/E ratio, plus performance, fundamentals and dividend history. Updated daily.

Track dividend stocks, analyze performance, and build your dividend portfolio with comprehensive stock data and analytics.

	NVO	LLY
Basics
Name	Novo Nordisk A/S	Eli Lilly and Company
Price	$38.65	$1,276.75
Sector	Health care	Health care
Market cap	large / 170,616,263	large / 1,201,877,550
Beta	0.35	0.45
Dividends
Dividend	$1.80	$6.69
Yield	4.65%	0.52%
Frequency	Bi-annually	Quarterly
Payout ratio	44.69%	21.24%
Dividend CAGR (3y)	20.43%	15.25%
Dividend CAGR (5y)
Dividend CAGR (10y)
Dividend safety score
Overall score
Forward payout ratio
Payout ratio/FCF
Dividend CAGR (3y)
Revenue CAGR (3y)
Debt/EBITDA
Debt/Equity
Valuation
P/E	9.61x	40.54x
P/S	3.37x	12.73x
P/B	5.36x	29.72x
P/CF	8.73x	46.91x
P/FCF	18.50x	92.49x
PEG ratio	-1.31x	3.13x
EV/EBITDA	5.82x	28.44x
Fundamentals
Gross margin	80.98%	83.79%
Operating margin	41.36%	45.56%
Pretax margin	42.24%	39.48%
Net margin	33.14%	31.66%
Tax rate	21.53%	19.79%
ROE	60.96%	97.85%
ROA	18.82%	18.35%
Interest coverage	19.57x	37.34x

	NVO	LLY
Basics
Name	Novo Nordisk A/S	Eli Lilly and Company
Price	$38.65	$1,276.75
Sector	Health care	Health care
Market cap	large / 170,616,263	large / 1,201,877,550
Beta	0.35	0.45
Dividends
Dividend	$1.80	$6.69
Yield	4.65%	0.52%
Frequency	Bi-annually	Quarterly
Payout ratio	44.69%	21.24%
Dividend CAGR (3y)	20.43%	15.25%
Dividend CAGR (5y)
Dividend CAGR (10y)
Dividend safety score
Overall score
Forward payout ratio
Payout ratio/FCF
Dividend CAGR (3y)
Revenue CAGR (3y)
Debt/EBITDA
Debt/Equity
Valuation
P/E	9.61x	40.54x
P/S	3.37x	12.73x
P/B	5.36x	29.72x
P/CF	8.73x	46.91x
P/FCF	18.50x	92.49x
PEG ratio	-1.31x	3.13x
EV/EBITDA	5.82x	28.44x
Fundamentals
Gross margin	80.98%	83.79%
Operating margin	41.36%	45.56%
Pretax margin	42.24%	39.48%
Net margin	33.14%	31.66%
Tax rate	21.53%	19.79%
ROE	60.96%	97.85%
ROA	18.82%	18.35%
Interest coverage	19.57x	37.34x

NVO vs. LLY Stock Comparison

NVO vs. LLY Stock Comparison

Popular comparisons